We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Reliability Reevaluated for Bladder Cancer Test Prognosis

By LabMedica International staff writers
Posted on 08 Nov 2016
Print article
Image: A blood film from a patient with bladder cancer showing increased number of neutrophils and band cells (Photo courtesy of MPH).
Image: A blood film from a patient with bladder cancer showing increased number of neutrophils and band cells (Photo courtesy of MPH).
A blood test that had shown promise in predicting how cancer will progress and what treatments will be most effective for a given patient may not be reliable for either, as results from previous studies are threatened by methodological limitations.

Preoperative risk stratification is a major challenge in bladder cancer (BC) and a robust biomarker is needed. One emerging candidate is the neutrophil-to-lymphocyte ratio (NLR). NLR is easily calculated from a complete blood count (CBC) and is felt to reflect the systemic inflammatory state.

Medical scientists at the University of Pennsylvania (Philadelphia, PA, USA) and their colleagues analyzed data that was collected in real-time during a prospective clinical trial, making it the first study of NLR in bladder cancer not to rely on observational data. The study analyzed SWOG 8710, which was a randomized Phase III trial of 317 patients with muscle-invasive bladder cancer. All patients were treated with radical cystectomies. Half had pre-surgery chemotherapy, while the other half did not.

Of the 317 total patients, the team identified 230 for a prognostic analysis to see if NLR could serve as a predictor of how long patients would live after curative treatment. They identified 263 others for a predictive analysis to see if NLR could tell which patients would respond to chemotherapy. There was a median follow-up of 18.6 years. For the prognostic analysis, NLR was not a significant factor in overall survival. The important factors were age and whether the patient received pre-surgery chemotherapy. For the predictive analysis, NLR did not predict which patients benefitted from chemotherapy.

Eric Ojerholm, MD, the lead author of the study, said, “The trial we used has a few big advantages to study NLR. First, baseline blood samples were collected as part of the trial protocol. Second, the study’s long-term follow-up gave us adequate ‘statistical power,’ meaning that if NLR really was a biomarker, then we should be able to detect it. Third, the trial randomly assigned some patients to receive pre-surgery chemotherapy. This allowed us to test NLR both as a prognostic and predictive biomarker.” The study was published on October 27, 2016, in the journal Cancer.

Related Links:
University of Pennsylvania

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Aspergillus Test
REALQUALITY Aspergillus
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.